|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500112658 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-18 09:45:05 |
|
注册时间: Date of Registration: |
2025-11-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项尿液氨基酸检测在健康人群筛查及泌尿系统疾患患者的早期诊断及预后管理中应用的观察性研究 |
|
Public title: |
An observational study of the use of a urine amino acid test in the screening of a healthy population and in the early diagnosis and prognostic management of patients with urologic disorders |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项尿液氨基酸检测在健康人群筛查及泌尿系统疾患患者的早期诊断及预后管理中应用的观察性研究 |
|
Scientific title: |
An observational study of the use of a urine amino acid test in the screening of a healthy population and in the early diagnosis and prognostic management of patients with urologic disorders |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
谢欣 |
研究负责人: |
谢欣 |
|
Applicant: |
Xie Xin |
Study leader: |
Xie Xin |
|
申请注册联系人电话: Applicant telephone: |
+86 10 6437 0045 |
研究负责人电话: Study leader's telephone: |
+86 10 6437 0045 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xx11149@rjh.com.cn |
研究负责人电子邮件: Study leader's E-mail: |
xx11149@rjh.com.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市瑞金二路197号 |
研究负责人通讯地址: |
上海市瑞金二路197号 |
|
Applicant address: |
No. 197, Ruijin 2nd Road, Shanghai |
Study leader's address: |
No. 197, Ruijin 2nd Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
|
Applicant's institution: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
|
Affiliation of the Leader: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)临伦审第(569)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属瑞金医院涉及人体的临床与科研项目伦理委员会 |
||
|
Name of the ethic committee: |
Ruijin Hospital Ethics Committee, Shanghai JiaoTong University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-24 00:00:00 |
||
|
伦理委员会联系人: |
赵彦琳 |
||
|
Contact Name of the ethic committee: |
Zhao Yanlin |
||
|
伦理委员会联系地址: |
上海市瑞金二路197号 |
||
|
Contact Address of the ethic committee: |
No. 197, Ruijin 2nd Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 80585870 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zyl02d86@rjh.com.cn |
|
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市瑞金二路197号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 197, Ruijin 2nd Road, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-selected topic (self-funded) |
||||||||||||||||||||||
|
Target disease: |
Prostate cancer, prostate hyperplasia, kidney cancer, renal vascular smooth muscle tumor |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
1.评估尿液氨基酸在不同泌尿系统疾患患者中的代谢特征,及其在早期筛查、疾病分期和预后管理中的相关性; 2.构建并验证适用于中国人群的尿液氨基酸参考范围,用于提升尿液氨基酸在健康人群疾病筛查的精准度。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To evaluate the metabolic profiles of urinary amino acids in patients with different urological disorders and their relevance in early screening, disease staging and prognostic management; 2.To construct and validate a reference range of urinary amino acids applicable to the Chinese population, which can be used to improve the accuracy of urinary amino acids in disease screening in healthy populations. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
病例组: 1.成人(>=18 岁),疑似或新确诊或曾接受过治疗的泌尿系统疾患患者(包括前列腺、肾、膀胱肿瘤、炎症或其他疾患); 2.愿意并能够为前瞻性数据收集提供知情同意书(或为回顾性数据使用提供现有同意书)。 正常健康人群: 1.成人(>=18 岁),未罹患良恶性肿瘤; 2.体检合格,无重要器官功能障碍; 3.肾功能正常,无蛋白尿。 |
||||||||||||||||||||||
|
Inclusion criteria |
Case Group 1.Adults (aged 18 or above), suspected or newly diagnosed or previously treated patients with urinary system disorders (including prostate, kidney, bladder tumors, inflammation or other disorders); 2. Willing and able to provide informed consent for the collection of prospective data (or provide existing consent for the use of retrospective data). Healthy and normal population Adults (aged 18 or above), without suffering from benign or malignant tumors; 2. Pass the physical examination and have no dysfunction of major organs; 3. Normal renal function and no proteinuria. |
||||||||||||||||||||||
|
排除标准: |
1.无法或不愿提供影像学资料或相关临床记录。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Unable or unwilling to provide imaging or relevant clinical records; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2030-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-12-01 00:00:00 至 To 2030-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |